Cenexa Labs has no affiliation with Professor Sikiric, Professor Goldstein, the University of Zagreb, or George Washington University, and this information does not constitute an endorsement of any products or services
doi: 10.1016/j.ijgfs.2024.101050 162
Gentle Handling: Remember, peptides are delicate
Several GLS inhibitors have been developed, among which CB-839 is currently undergoing clinical trials as a potent, orally bioavailable GLS-selective inhibitor for the treatment of various cancers, including TNBC, NSCLC, and colon cancer (NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600, NCT03057600)
Bacterial endotoxins, he says, can do a "serious number on you"